12 results about "Binding iron" patented technology

Methods of increasing systemic iron availability in a human subject using plant-derived ferritin-bound iron are provided. In certain embodiments, ferritin-bound iron is orally administered in an amount effective to produce sustained systemic iron exposure characterized by measurable serum iron levels at least 24 hours after administration. In some embodiments, administration produces a delayed peak serum iron concentration and provides controlled systemic iron delivery relative to conventional iron supplements. In certain embodiments, administration of ferritin-bound iron results in a reduced hepcidin response relative to ferrous sulfate, thereby facilitating improved iron utilization. The ferritin-bound iron may be absorbed through receptor-mediated uptake mechanisms that provide controlled intracellular iron release and sustained systemic availability. The methods are useful for increasing systemic iron availability and for treating or preventing iron deficiency and iron deficiency anemia in human subjects.

The invention relates to a method for preparing a nano metal iron oxide material from iron ion binding protein with specific binding capacity, and belongs to the technical field of genetic engineering. In order to overcome the technical problems of non-specific binding of metallothionein and iron ions and relatively low production efficiency in a traditional nano # imgabs0 # biological preparation method, the invention provides an iron ion binding protein with specific binding capacity, and a specific binding iron ion polypeptide sequence is connected on the basis of metallothionein, so that the iron ion binding protein with specific binding capacity is obtained. The specific binding amount of iron ions is increased, and the specific binding iron ion protein is used as a template to prepare the # imgabs 1 # nano material. According to the method for preparing the nano-metal iron oxide material through specific binding of the iron ion protein, reaction conditions are mild, # imgabs2 # is prepared and synthesized in an oriented mode through high selectivity of the specific binding iron ion protein, the preparation process is easy to control, and the particle size range of the prepared # imgabs3 # is 20-1000 nm.

This invention provides methods for quantitatively determining the concentration of free iron and ferritin-bound iron in a sample. The method includes diluting a ferritin-containing sample with a diluent to create a slurry, processing the slurry through a crossflow filtration system equipped with a membrane of at least 500 kilodaltons molecular weight cutoff, collecting the permeate containing free iron and the retentate containing ferritin-bound iron analyzing the iron concentrations in the permeate and retentate using a suitable analytical technique and calculating the mass balance of the total iron content. The invention also provides an antibody for use in quantitating the amount of ferritin in a sample and methods of treating iron deficiency in a patient in need thereof.

Disclosed is a method of producing a non-naturally occurring peptide for reducing nitrogen, the method comprising: a) identifying a first group of peptides each having a binding pocket similar to a naturally occurring iron-sulfur cluster cofactor binding pocket of a naturally occurring nitrogenase, wherein each of the first group of peptides is not a nitrogenase or a subunit or domain of a nitrogenase; b) selecting, from the first group of peptides, a second group of peptides each having at least one target amino acid in the binding pocket; c) selecting, from the second group of peptides, a third group of peptides each having at least one target property; and d) modifying the sequence and / or structure of each of the third group of peptides to improve binding of the iron-sulfur cluster cofactor in the binding pocket. Also disclosed is a non-naturally occurring peptide for reducing nitrogen, comprising: at least one modification to a naturally occurring peptide; and a binding pocket for binding an iron-sulfur cluster cofactor; wherein the naturally occurring peptide is not a nitrogenase or a subunit or domain of a nitrogenase; and wherein the at least one modification improves binding of the iron-sulfur cluster cofactor in the binding pocket.

The present invention relates to a matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, a ferroportin blocker, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of the following: systemic iron levels, transferrin saturation (Tsat), non-transferrin-bound iron (NTBI), and unstable plasma iron (LPI). This may occur by inhibiting the expression of a target gene, where the target gene may be a transmembrane protease, serine 6 (TMPRSS6). Furthermore, the present invention relates to compositions comprising the above compounds, and methods of using such compounds and / or compositions. Such use may include therapeutic use, for example, to reduce iron overload and prevent iron-related toxicity, before, during, or after chemotherapy pretreatment, stem cell transplantation, and engraftment.

The present application relates to the technical field of biological medicine manufacturing, and particularly relates to a method for extracting high-solubility ovotransferrin from egg white, wherein the egg white is diluted with water, FeCl3 solution is added, NaOH solution is used to adjust the pH of the solution, and high-speed shearing is performed; the pretreated egg white solution is subjected to ultrasonic and high-voltage alternating electric field treatment; anhydrous ethanol is added, the supernatant is obtained by centrifugation, and ultrafiltration is performed; water is added for concentration, and a crude ovotransferrin solution is obtained; resin is added to the crude ovotransferrin solution, citric acid solution is used to adjust the pH, and the resin is removed by filtration, so that a filtrate is obtained; PEG8000 is added, the pH is adjusted, and the precipitate is obtained by centrifugation; the precipitate is dissolved in water, and ultrafiltration is performed; water is continuously added for concentration, so that concentrated ovotransferrin is obtained. The extracted ovotransferrin has high solubility and iron binding capacity, can bind with iron elements again to prepare ovotransferrin iron preparation for improving iron deficiency anemia, the whole preparation process is green and environmentally friendly, has low cost, and can be mass-produced in an industrialized manner.

This utility model discloses a production device for dietary transferrin, comprising a main body of the production device, which includes a reactor one and a filter three. The main body also includes a reaction production mechanism, which includes a filter assembly one disposed on one side of the reactor one, a reaction assembly one disposed on one side of the filter assembly one, and a filter assembly two disposed on one side of the reaction assembly. By designing the reaction production mechanism, the product can undergo internal reaction and acid-base adjustment in reactors one and two during production. Utilizing the characteristic of dietary transferrin to lose iron ions in acidic conditions and bind iron ions in alkaline conditions, dietary transferrin with different iron saturations can be prepared. Simultaneously, during the filtration process of filters one, two, and three, the dietary transferrin reaction solution is recycled through a dual filtration device.

The invention belongs to the field of bioanalytical chemistry and drug metabolism research, and discloses a typing quantitative detection method for different forms of iron in serum, which comprises the following steps: S1, mixing a to-be-detected serum sample with an inorganic chlorine salt solution, placing in an ultrafiltration centrifuge tube, standing, centrifuging, and taking filtrate as non-transferrin binding iron NTBI; s2, a weak acid solution of inorganic chlorine salt is added into the filter residues obtained in S1, centrifugation is conducted, and filtrate serves as transferrin binding iron TBI; s3, a mixed solution of a reducing agent solution and an inorganic chlorine salt solution is added into the filter residues obtained in the S2, centrifugation is conducted, and filtrate serves as drug binding iron DI; and S4, respectively measuring absorbance of the NTBI, TBI and DI parts by adopting a spectrophotometric method, and converting the concentration by combining a standard curve, so as to obtain the content of the NTBI, TBI and DI in the serum sample to be detected. The method realizes high-selectivity separation and accurate quantification of three different forms of iron, and is suitable for intravenous iron agent in-vivo behavior research and analysis of iron metabolism related mechanisms.

This invention provides methods for quantitatively determining the concentration of free iron and ferritin-bound iron in a sample. The method includes diluting a ferritin-containing sample with a diluent to create a slurry, processing the slurry through a crossflow filtration system equipped with a membrane of at least 500 kilodaltons molecular weight cutoff, collecting the permeate containing free iron and the retentate containing ferritin-bound iron analyzing the iron concentrations in the permeate and retentate using a suitable analytical technique and calculating the mass balance of the total iron content. The invention also provides an antibody for use in quantitating the amount of ferritin in a sample and methods of treating iron deficiency in a patient in need thereof.

This invention relates to the field of protein extraction technology, specifically disclosing a method for the simultaneous co-production and extraction of egg white lysozyme and ovotransferrin, comprising: (1) Egg white pretreatment: after dilution, adjust the pH to 4.5, filter out the ovomucin precipitate, and then adjust the supernatant to pH 8.0-9.0. (2) Cation exchange separation of lysozyme: adsorb onto a cation exchange column of the pretreatment solution, collect the permeate and eluent as the egg white flow-through solution; elute the lysozyme, and obtain the lysozyme product by concentration, desalting, sterilization, and drying. (3) Anion exchange separation of ovotransferrin: after adjusting the flow-through solution to pH 5.5-6.0, load onto an anion exchange column, elute to remove impurities, and collect the permeate containing ovotransferrin. (4) Iron removal and drying: concentrate by ultrafiltration, dialyze with citrate buffer for desalting and preliminary iron removal, then remove bound iron by chelating resin, and dry to obtain the iron-free ovotransferrin product.

This invention provides methods for quantitatively determining the concentration of free iron and ferritin-bound iron in a sample. The method includes diluting a ferritin- containing sample with a diluent to create a slurry, processing the slurry through a crossflow filtration system equipped with a membrane of at least 500 kilodaltons molecular weight cutoff, collecting the permeate containing free iron and the retentate containing ferritin-bound iron analyzing the iron concentrations in the permeate and retentate using a suitable analytical technique and calculating the mass balance of the total iron content. The invention also provides an antibody for use in quantitating the amount of ferritin in a sample and methods of treating iron deficiency in a patient in need thereof.

The present invention relates to a Matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, an iron transporter blocking agent, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of systemic iron levels, transferrin saturation (Tsat), non-transferrin binding iron (NTBI), and labile plasma iron (LPI). This can be accomplished by inhibiting the expression of a target gene, wherein the target gene can be transmembrane protease serine 6 (TMPRSS6). Further, the invention relates to compositions comprising said compounds and to methods of using such compounds and / or compositions. Uses may include therapeutic uses, such as for reducing iron overload and preventing iron-related toxicity before, during or after chemotherapy pretreatment, stem cell transplantation and colonization.